A Comprehensive Review on Floating Drug Delivery System

[1]Ankita, [1*]Panshul Sharma, [1]Hans Raj

[1]IEC School of Pharmacy, IEC University Baddi, Solan-174103, Himachal Pradesh, India.

**Corresponding author: Panshul Sharma, IEC School Of Pharmacy, IEC University, Baddi.*
sharmapanshul17@gmail.com

Abstract:

For drug delivery to the systemic circulation, the oral route is the most suitable and widely used. This course has high worthiness for patients, especially because of the simplicity of organization. In the pharmaceutical industry, controlled release drug delivery systems that release the drug at a predetermined rate have played a major role in the development of oral dosage forms over the years. For drugs that have a shorter gastric residence time and poor bioavailability, a variety of strategies have been developed and implemented. The floating drug delivery system, on the other hand—one of the most widely used methods of the gastro retentive drug delivery system—has an advantage for drugs that are primarily absorbed in the stomach and duodenum, which are the upper parts of the gastrointestinal tract.The different kinds of floating drug delivery systems, as well as the idea behind and how they work to get gastric retention. Innovative drug delivery technologies are being used and are available for clinical use in the in vitro and in vivo studies used to evaluate the potential, performance, and application of floating systems to solve a variety of issues that arose during the development of a dosage form. One of the gastro-retentive dosage forms used to extend gastric residency consists of floating drug delivery systems (FDDS), which were used to compile the most recent literature with a particular focus on the primary floating mechanism for achieving gastric retention. Drugs that are absorbed from the upper gastrointestinal tract and those that function locally throughout the stomach benefit greatly from sustained oral release of gastrointestinal dosage types. The physiology, factors influencing gastric retention time, excipient variables influencing gastric retention, strategies for designing a single-unit, hydrodynamically balanced system, and a multi-unit floating structure, as well as aspects of their classification, factors affecting, Applications, Mechanism, Methods of Prepration, Evaluation and advantages, disadvantages are all covered.

Keywords:systemic circulation,predetermined rate, gastric residence time, bioavailability, duodenum, gastro-retentive dosage forms, floating drug delivery systems.

1. Introduction:(1-13)

The vast majority of the medication are accessible in market are as oral medication conveyance framework on account of its expense viability, consistence of patient and simple to oversee however because of some unfortunate bioavailabilityissues and extremely high

gastric purging rate its utilization is exceptionally restricted for gastric locale illness and the sickness whose therapy needs great plasma centralization of medication. A portion of the medication are limited retention window at upper degree of gastrointestinal. Gastric emptying time is controlled or prolonged by dosage. In order to overcome this obstacle, the medication's distribution needs to provide a longer duration of action during stomach residency. The hour of prescription delivery is improved, drug squander is decreased, and drug dissolvability is improved for drugs that are less solvent in high encompassing pH to gastro maintenance. There would be fewer side effects and no need for multiple dosages with this method of drug delivery. The drug's gastric retention time is increased because the gastrointestinal retentive system remains in the stomach for specific hours. The drug's bioavailability and solubility are improved, and drug waste is reduced.A framework which is a piece of gastro retentive framework known as drifting medication conveyance framework is a hopeless framework that works in light of lightness framework in stomach which builds the gastric home season of medication consequently expands the medication viability. Due to its functioning in view of lightness guideline this framework likewise called as hydro progressively controlled framework as a result of it gives a consistent stream and arrival of medication which gives a climb in the retention of specific medication. Drifting medication conveyance framework makes sense of about framework that have low thickness, results having more lightness to drift over gastric liquid and helps in keeping up with drugs gastric home time subsequently make drug more inclined to give longeraction. Light framework is created based on granules, powder, cases, tablet, covered movies, and empty microsphere. Drugs that have explicit assimilation in upper gastrointestinal locale explicitly and having exceptionally high dissolvability in the acidic condition are more appropriate for planning in type of drifting framework. Drifting multi particulate are gastro retentive medication free streaming proteins having size more modest than 200 micrometer. Drifting multi particulate are gastro retentive medication conveyance framework plan as bubbly and non-bubbly drifting medication conveyance framework. Drifting medication conveyance can be made in the fork of tablet and case drug gradually delivers at a consistent ratefrom the framework.

2. Classifications:(14-23)

2.1 Effervescent system: -

These are lattice kinds of frameworks arranged with the assistance of swellable polymers (methylcellulose and chitosan) and different bubbly compounds (sodium bicarbonate,tartaric corrosive, and citrus acid).They are formed so that when interacted with acidic gastric items, co2 free and gas captured in enlarged hydrocolloids which gives lightness to the measurements structure.

2.1.1 Volatile liquid containing systems:

An inflatable chamber containing a liquid (such as ether or cyclopentane) that gasifies at body temperature to cause the inflammation of the chamber in the stomach can be included in a drug delivery system to maintain the GRT. A plug made of PVA, polyethylene, and other bio-erodible materials may also be included in the device. that gradually dissolves, resulting in the inflatable chamber releasing gas and collapsing after a predetermined amount of time to allow the inflatable systems to spontaneously exit the stomach.

2.1.2 Gas generating systems:

Carbon dioxide (CO2) is trapped in the systems' gelling matrix as a result of effervescent reactions between carbonates/bicarbonates salts and citric/tartaric acid in these systems. In this way diminishing its particular gravity and coming to drift over the gastric liquid.

2.1.2.1 Floating pills: The inner effervescent layer of these systems is made up of sodium bicarbonate and tartaric acid, and the outer swellable polymeric membrane is made up of polymers. To keep tartaric acid and sodium bicarbonate from coming into physical contact, the inner layer is further divided into two sublayers. When this pill is submerged in buffer solution at 37°C, it settles to the bottom, and the outer swellable membrane allows buffer solution to enter the effervescent layer. The reaction between tartaric acid and sodium bicarbonates produces carbon dioxide, which results in the formation of pills or balloons that are swollen. The device floats because the generated carbon dioxide is trapped in the delivery system. The drug is released in a controlled manner and these systems were found to float completely within ten minutes, regardless of pH or medium viscosity.

2.1.2.2 Floating capsules: Drifting cases are ready by filling a combination of sodium alginate and sodium bicarbonate, these float because of the age of carbon dioxide which gets caught in the hydrating gel network on openness to an acidic climate.

2.1.2.3 Floating systems with ion exchange resins: By combining the beads with a solution of sodium bicarbonate, an ion exchange resin loaded with bicarbonate is used to formulate these systems. A semipermeable membrane was then used to surround these loaded beads to prevent a sudden loss of carbon dioxide. There is an exchange of chloride and bicarbonate ions when the beads come into contact with the contents of the stomach. This causes carbon dioxide to be produced, which moves the beads toward the top of the stomach and creates a floating layer of resin beads that releases the drug at a predetermined time.

2.2 <u>Non-effervescent systems:</u>

After swallowing, this type of system expands without restriction. Imbibition’s of gastric liquid to a degree that it keeps their exit from the stomach. Due to their tendency to remain lodged close to the pyloric sphincter, these systems may be referred to as the "plug type system." Mixing the drug with a gel is one way these dosage forms are made. The gel swells when it comes into contact with the drug after it is swallowed, keeps its shape, and has a bulk density of less than 1. This is based on how GIT polymer or bio adhesion swells up against the mucosal layer. Gel-forming materials like polycarbonate, polyacrylate, and polystyrene are the most frequently utilized excipients. This hydrocolloid begins to hydrate by initially forming a gel on the dosage form's surface. The resultant gel structure then, at that point, controls the pace of dispersion of dissolvable in and drug-out of the measurements structure. The different sorts of this framework are as per the following:

2.2.1 Single layer floating tablets: This can be made by intimately mixing the drug with a gel-forming hydrocolloid that swells when it comes into contact with gastric fluid and keeps the bulk density below 1. These dosage forms are buoyant because the swollen polymer traps air.

2.2.2 Bilayer floating tablets: A bilayer tablet has two layers: an immediate release layer that releases the initial dose from the system and a sustained release layer that absorbs gastric fluid and maintains a bulk density of less than one, keeping it buoyant in the stomach (Fassihi

and Yang invented a zero-order controlled release). Multilayer tablet with at least two drug layers and two barrier layers. Every one of the layers are made of swellable, erodible polymers and the tablet was found to expand on contact with fluid medium. The barrier layers eroded away as the tablet disintegrated, exposing more of the drug. Gas developing specialist is added in both of the boundary layers, this made the tablet float and expanded the maintenance of tablet in a patient's stomach.

2.2.3 Colloidal gel barrier systems: It contains medication with hydrocolloids that gel together and are designed to keep stomach contents buoyant. Hydrocolloids of the cellulose type that are highly swellable are present in abundance in this system. The system's hydrocolloids hydrate upon contact with gastric fluid, forming a colloidal gel barrier around the gel's surface. This dosage form's buoyancy comes from the air that is held inside by the swollen polymer, which keeps its density below unity.

2.2.4 Microporous Compartment System: The encapsulation of the drug reservoir within a microporous compartment with openings along its top and bottom walls is the foundation of this technology. The drug reservoir compartment's peripheral walls are completely sealed to prevent the undissolved drug from coming into direct contact with the gastric mucosal surface. The delivery system floats over the contents of the stomach because of the entrapped air in the floatation chamber. Through the openings, gastric fluid enters, dissolves the drug, and then transports the dissolved drug continuously throughout the intestine for absorption.

2.2.5 Alginate beads: To foster Multi-unit drifting measurements frames the freeze-dried calcium alginate has been utilized. Round dots of roughly 2.5 mm in measurement can be ready by the precipitation of calcium alginate through dropping sodium alginate arrangement into fluid arrangement of calcium chloride. After that, the beads are snapped, frozen in liquid nitrogen, and freeze-dried for 24 hours at -40°C. This creates a porous system that can keep a floating force for 12 hours. On the other hand, multiple-unit dosage forms appear to be better suited because they are said to reduce dose-dumping and intersubject variability in absorption.

2.2.6 Hollow microspheres: The outer polymer shelf of hollow microspheres was filled with drug using a novel emulsion solvent diffusion method. The ethanol: The drug and enteric acrylic polymer dichloromethane solutions are poured into a 40°C-controlled agitated aqueous solution of PVA. The gas phase that is generated in the dispersed polymer droplet by the evaporation of dichloromethane forms the internal cavity in the polymer with drug microspheres. For more than 12 hours, the surfactant-containing acidic dissolution medium's surface was continuously covered by the micro balloons. pH 7.2 produced more drug than pH 6.8 did. A novel emulsion-solvent diffusion technique was used to create hollow microspheres, also known as micro balloons, whose outer polymer shells contained ibuprofen.

3. Mechanism:(24,25)

The drug is slowly released from the system at the desired rate while the system is floating on the gastric contents. The stomach expels the remaining system following the drug's release. However, in addition to having a small amount of gastric content, the dosage form must also have a small amount of floating force in order to remain consistently buoyant on the meal's

surface. A novel apparatus for determining the resultant weight has been described in the literature for measuring the floating force kinetics. The apparatus works by continuously measuring the force, equivalent to F, that is required to maintain the submerged objects over time. In order to avoid the negative effects of unanticipated intragastric buoyancy capability variations, the apparatus assists in optimizing FDDS in terms of stability to stability and durability of produced floating forces.

$$F = F_{buoyancy} - F_{gravity}$$
$$= (D_f - D_s)\, g\, v$$

Where,

F = Total vertical force,

D_f = fluid density,

D_s = object density,

V = volume

4. Approaches to design the various floating dosage form:(26-31)

Two types of floating Dosage systems Single- and multiple-unit floating dosage systems have been designed by using the following approaches.

4.1. Single-unit dosage forms:

4.1.1 Low-density approach

In this methodology, the globular shells with thickness lower than that of gastric liquid can be utilized as transporter for drug for making single-unit drifting dose structure. Coated shells have utilized poprice, polystyrol, and popcorn as drug carriers26. For the undercoating of these shells sugar polymeric materials, for example, methacrylic polymer and cellulose acetic acid derivation phthalate have been taken advantage of. The drug polymer mixture is then applied to these shells for an additional coating. Either hydroxypropyl cellulose or the polymer ethyl cellulose can be used, depending on the kind of release you want. The item drifts on the gastric liquid and steadily delivers the medication for a significant stretch of time.

4.1.2 Fluid- filled floating chamber

A microporous component that covers the drug reservoir is combined with a gas-filled floatation chamber in these dosage forms. An opening for the GIT fluid to enter the device to dissolve the drug is provided along the top and bottom walls. To ensure that the drug does not dissolve, the side walls that come into contact with the fluid are sealed. Air or any other suitable gas, liquid, or solid with an appropriate specific gravity and that is inert could serve as the floatation fluid in the system. The size of this device should be adjustable. The device floats in the stomach for a long time before slowly releasing the medication. The shell eventually breaks down, travels to the intestine, and is then eliminated from the body after the drug has completely released.

4.1.3 Hydrodynamically balanced systems (HBS)

These frameworks upgrade the retention since they are planned to such an extent that they stay in GIT for draw out time. Drugs which have a superior solvency in acidic climate and site-explicit retention in the upper piece of GIT are reasonable contender for such frameworks. These measurements structures should have a mass thickness of under 1. It

ought to keep up with its primary respectability and ought to continually deliver the medication. Chlordiazepoxide hydrochloride29 has a solubility of less than 0.1 mg/mL at neutral pH and a solubility of 150 mg/mL at pH 3 to 6, making the HBS capsule of this medication an excellent choice to address the solubility issue.

4.1.4 Bilayer and matrix tablets

Floatable properties are also demonstrated by some forms of matrix and bilayer tablets. The polymers which have been taken advantage of are sodium carboxymethylcellulose (CMC), hydroxypropyl cellulose, Hydroxypropyl methylcellulose, ethyl cellulose and Cross povidone.

4.1.5 3-layer principle

The 3-layer principle has been improved by the creation of a drug delivery system with an asymmetric configuration. This allows for the attainment of zero-order release kinetics and the modulation of the release extent. The plan of the framework is with the end goal that it floats on the stomach content and drag out gastric home time which further outcomes in longer all out-travel time which augment the absorptive limit and consequently better bioavailability is accomplished. These advantages may be applicable to medications with a narrow absorption window, medications that are absorbed through an active transport mechanism from the small intestine, or medications with a pH-dependent solubility.

4.2. Multiple-unit dosage forms:

The goal of the multiple-unit dosage form is to create a dependable formulation that combines the advantages of a single-unit form with the drawbacks of a single-unit form. Due to their high loading capacity, microspheres have been utilized. For the production of microspheres, polymers like albumin, starch, gelatine, polyacrylamide, polymethacrylate, and polyalkylcyanoacrylate have been utilized. Because of their characteristic hollow internal structure, microspheres exhibit excellent in vitro floatability. Recent patent literature has described a number of carbon dioxide multiple-unit oral formulations with features that are expanded, extended, or inflated by carbon dioxide generated in the devices following administration.

5. FACTORS AFFECTING GASTRIC RETENTION:(32)

5.1. Physiological factors:

5.1.1 Density: The dosage form's buoyancy, which is influenced by the density, is a function of the gastric retention time. Because it is further from the pyloric sphincter, a buoyant dosage form has a density that is lower than that of the gastric fluids. As a result, the dosage unit remains in the stomach for an extended period of time. It has been reported to have a density of less than 1.004g/ml, or less than the contents of the stomach.

5.1.2 Size: It has been reported that dosage form units with a diameter of more than 7.5 millimetres have a higher GRT than those with a diameter of 9.9 millimetres.

5.1.3 Shape of dosage form: According to reports, devices in the tetrahedron and ring shapes with a flexural modulus of 48 and 22.5 kilo pounds per square inch (KSI) have better GRT retention at 24 hours—90% to 100 percent—than those in other shapes.

5.2 Biological factors:

5.2.1 Fed or unfed state: Periods of intense motor activity or the migrating myoelectric complex (MMC) that occur every 1.5 to 2 hours during fasting characterize GI motility. Undigested food is removed from the stomach by the MMC. However, MMC is delayed and GRT takes a significantly longer time in the fed state.

5.2.2 Nature of meal: The motility pattern of the stomach can shift to a fed state when indigestible polymers or fatty acid salts are fed, resulting in a slower rate of gastric emptying and prolonged drug release.

5.2.3 Caloric content:A meal high in fats and proteins can extend GRT by four to ten hours.

5.2.4 Frequency of feed: Due to the low frequency of MMC, the GRT can rise by over 400 minutes when multiple meals are given instead of just one.

5.2.5 Gender/ Age: Mean wandering GRT in guys (3.4±0.6 hours) is less contrasted and their age and race matched female partners (4.6±1.2 hours), no matter what the weight, level and body surface. The elderly has a shorter gastric emptying time than younger subjects. Gastric and intestinal transit times also vary between subjects and within subjects. The GRT of the elderly, particularly those over 70, is significantly longer.

5.2.6 Posture: The patient's supine and upright ambulatory states can have different effects on GRT. An upstanding position safeguards drifting structures against postprandial exhausting on the grounds that the drifting structure stays over the gastric items independent of its size. Large dosage forms exhibit prolonged retention in supine subjects. The gastric maintenance of drifting structures seems to stay light anyplace between the lesser and more noteworthy shape of the stomach. These units may be swept away by the peristatic movements that push the gastric contents toward the pylorus when they move distally, resulting in a significant decrease in GRT when compared to upright subjects.

5.2.7 Concomitant drug administration: An oral dosage form's gastric emptying and, consequently, gastric residence time are affected by anticholinergics like atropine and propantheline opiates like codeine and prokinetics like metoclopramide and cisapride.

6. Methods for Preparing Floating Dosage Form:(32)

6.1. Direct compression technique: Includes compacting tablets straightforwardly from powdered material without adjusting the actual idea of the actual material. Direct pressure vehicles or transporters should have great stream and compressible characters these properties are granted by inclining these vehicles toward slugging, splash drying or crystallization. Di calcium phosphate trihydrate, tri calcium phosphate, and so on are the most common carriers.

6.2. Melt granulation technique:A melt-able binder is used to agglomerate pharmaceutical powders, and neither water nor organic solvents are required for granulation. Since there is no drying step, the interaction is less tedious and utilizes less energy. Granules were ready in a lab scale high shear blender, utilizing a coat temperature of 60 °c and an impeller speed of 20000 rpm.

6.3. Melt solidification technique: The molten mass is emulsified in the aqueous phase during this procedure, and then it is chilled to solidify. The transporters utilized for this strategy are

lipids, waxes, polyethylene glycols. Drug is integrated into these transporters to accomplish controlled discharge.

6.4. Wet granulation technique: The wet massing of powders, wet sizing or milling, and drying are all part of the wet granulation process. Wet granulation frames the granules by restricting the powders along with a glue rather than compaction. A solution suspension or slurry containing a binder is used in the wet granulation method. Typically, the binder is added to the powder mixture, but the binder can also be added to the dry powder mix and the liquid can be added by itself. Since the mass should merely be moist rather than wet or pasty, and there is a limit to the amount of solvent that can be utilized, the method of introducing the binder depends on its solubility and the components of the mixture. Mixing continues after the granulating liquid is added until a uniform dispersion is achieved and all of the binder has been activated. After that, the wet mass is processed through a hammer mill or multifil with large perforated screens for wet screening. The processed wet mass is dried by either utilizing plate drier or fluidized bed drier, after complete the drying oil materials is mixed with dried granules. This greased up granules is made to go through pressure.

6.5. Effervescent technique: The effervescent reaction between organic acid (citric acid) and bicarbonate salts can fill the drug delivery system's floating chamber with CO2, an inert gas.

6.6. Spray drying techniques: It involves spraying the core-coating mixture into the environment to cause the coating to solidify and dispersing the core material in a liquefied coating material. The coating material's solubility in the solvent evaporates quickly during solidification.

7. EvaluationofFloatingDrugDeliverySystem:(33-36)

7.1 Bulk Density: It is the ratio of the powder's bulk volume (Vo) to its total mass (m).

Db=m/V

7.2 Tapped Density: The ratio of the total mass of powder (m) to the powdered volume (Vi)

Dt=m/V

7.3 Compressibility Index: The powder's bulk density (ρo) and tapped density (ρt) as well as the rate at which it packed down can be used to assess its flowability. Compressibilityindexcalculated.

Where,

ρo=Bulkdensityg/ml,

ρt=Tappeddensityg/ml.

7.4 Hauser's Ratio: Utilizing the following formulas, it is divided by bulk density for evaluation by means of taking Tapped Density.

Hauser'sRatio=Tappeddensity/Bulkdensity

7.5 Angle of Repose: The angle of repose is a method for measuring the tensile forces in powder or granules. This is the greatest angle that can be drawn between the horizontal plane and the powder or granule surface. Granules are allowed to move through the funnel, which is set at a predetermined height (h).The angle of repose was then calculated by measuring the height and radius of the formed grains.

Tan θ=(h/r) or θ=tan^{-1}(h/r)

Where,
θ=angle of repose
h=height of the heap
r=radiusoftheheap

7.6 Hardness:A tablet's hardness demonstrates its resistance to mechanical shocks during handling. The Monsanto hardness tester was used to evaluate the tablets' hardness. Itwasexpressedinkg/cm2.Three tablets were selected at random, and the tablets' hardness was determined.

7.7 Friability test: The friabilityoftabletswasevaluatedbyusingRocheFriabilator. It wasexpressedinpercent(%).Ten tablets were initially weighed (W) and placed in a friabilator. The friabilator wereoperatedat25rpm for4minutesorrunasmuchas100revolutions. Thetabletshavebeenweighedagain(Wo).The %friabilitywasthencalculatedbyusingformula:

%F=100(1-Wo/W)

%Friabilityoftabletslessthan1%wasconsidereddesirable

7.8 Tablet Density: Tablet density was an excellent parameter for floating tablets. The tablet could float most effective when its density turned into much less than that of gastric fluid (1.004). The density was determined by the usage of following formula:

V=лr2h

d=m/v

Where,
v=volumeoftablet(cc)
r=radiusoftablet(cm)
h=crownthicknessoftablet(g/cc)
m =massoftablet

7.9 Weight Variation test: In order to check for weight variation, ten tablets were chosen at random from each batch and weighed separately. The United States Pharmacopoeia allowed for some variation in a tablet's weight.

7.10 Determination of Buoyancy lag time: The buoyancy lag is the time it takes for the tablet to float and come out of the water. Thebuoyancyoftabletswasstudiedat37±0.5ºcin900mlofsimulatedgastricfluid.Thebuoyancylagtimewasdeterminedbytheusageofstopwatchandoverall floating timewasobservedvisually.

7.11Floating time: Floating time was measuredbytheuseofUSPdissolutionapparatus-IIat50rpmusing900mlof0.1NHClandtemperaturewassetat37±0.5ºC,throughoutthestudy.
Visual observation is used to measure the duration of floating (floating time), which is the time during which the tablet floats within the dissolution medium (including floatinglag time, which is the time required for the tablet to set on the surface).

7.12SwellingIndex: Swellingstudywascarriedoutforthefloatingsustainedreleaselayertablets.
The precisely weighed tablets were placed in the USP dissolution apparatus II, which contained 900 millilitres of 0.1NHCl, was kept at 37 degrees Celsius, and they were allowed to expand until they reached a constant weight. The device had been removed, blotted with

filter paper, and weight changes had been determined. Theexperimentswereperformedintriplicate. The formula was then used to determine the degree of swelling (the swelling index).

SWELLINGINDEX=Wg-W0/Wo=100

Where,Wo is the initial weight of tablet and Wg is the weight oftabletatequilibrium swellinginthemedium.

7.13 Drug Content:Five tablets were selected at random from a batch, weighed, and ground up in mortar. Anaccuratelyweighedquantityofpowderedtabletsequivalentto100mgwastakeninastandardflask andthevolumewasfilledup tothemarkwith0.1NHCL;thesolutionwasfilteredthrougha0.45um membranepaper. The spectrophotometric method was used for the analysis.

8. Application of floating drug delivery system:(37)

8.1 Enhanced Bioavailability: When compared to the administration of non-GRDFCRpolymeric formulations, the bioavailability of riboflavinCR-GRDF is significantly increased.

8.2 Sustained Delivery of Drugs: OralCR formulations encountered issues in the GI tract, such as gastric residence time. Most of the time, these issues can be solved by HBS systems that can stay in the stomach for a long time, have a bulk density of less than one, and can float on the gastric contents.

8.3 Site specific drug delivery system: The controlled, gradual delivery of the drug to the stomach results in appropriate local therapeutic rates and a reduction in the drug's systemic exposure.Thedosingfrequencycanbedecreasedbyextendedgastricavailabilityfrom asitedrivendrugdeliverysystem. E.g. FurosemideandRiboflavin.

8.4 Improvement of Absorption: By optimizing their absorption, drugs with low bioavailability due to site-specific absorption from the upper GIT can be developed as floating drug delivery systems.

8.5Minimized adverse reaction at the colon: The amount of drug that enters the colon is reduced by drug retention in the stomach in HBS. Unwanteddrugactivityinthecolonregioncanthusbeavoided.

8.6 Reduced drug concentration fluctuation: When compared to forms of immediate release dosing, continuous administration of the drug within a narrower range results in a blood drug concentration.

9.Advantages of FDDS:(38-42)

- The treatment of stomach-related disorders greatly benefits from FDDS. Because creating a gastro retentive product—one that has a longer retention time in the stomach—is the primary goal of these systems.
- This method allows for the effective administration of medications with extremely short half-lives.
- Upgrade of the bioavailability for drugs which can used in the upper GIT.
- They additionally enjoy an upper hand over the ordinary framework as it tends to be utilized to defeat the difficulties of gastric maintenance time as well as the gastric discharging time.

- The duration of treatment with a single dose, which spreads out the active ingredient over a longer period of time. The active ingredient is specifically delivered to the site of action, reducing or eliminating side effects.

10. Disadvantages of FDDS:(38, 43-45)

- The significant drawback of drifting framework is necessity of an adequate elevated degree of liquids in the stomach for the medication conveyance to drift. Anyway, this constraint can be overwhelmed by covering the measurement structure with the assistance of bio adhesive polymers that effectively stick to the mucosal coating of the stomach.
- Numerous factors, including food presence, pH, and gastric motility, influence gastric retention. These variables are never steady and thus the lightness can't be anticipated.
- For use in floating drug delivery systems, medications that irritate and irritate the gastric mucosa are not suitable.
- Due to its all-or-non-emptying process, there is a lot of variation in gastric emptying time.
- Patients ought not be dosed with drifting structures not long prior to hitting the sack.
- For medications that have a problem with solubility (or stability) in gastric fluids, a floating system is not an option.
- The measurement structure ought to be regulated with at least glass loaded with water (200-250 ml).
- The drugs, such as Nifedipine, Propranolol, and others, that are absorbed throughout the GIT undergo first-pass metabolism. aren't a good candidate.

11. Recent advances in floating dosage forms:(37, 46)Theprocessoffloatinganddrugrelease behaviour ofpoly(vinylacetate)- basedfloatingtabletswithmembrane-controlled drugdeliverywerestudiedbyStrubingetalinvestigatedthecomponent offloatinganddrugreleasebehaviourofpoly(vinylacetate)- basedfloatingtabletswithmembrane-controlleddrugdelivery. With regard to drug release in 0.1 mol/lHCl, researchers investigated tablets containing propranololHCl and Kollidon®SR as an excipient for direct compression and various Kollicoat®SR30D/Koll coat®IR coats ranging from 10 to 20 mg polymer/cm2. Furthermore,theonsetoffloating,thefloatingdurationandthefloatingstrengthofthedeviceweredetermined. Benchtop MRI tests on a few selected materials were also carried out. In addition,benchtopMRIstudiesofselectedsampleswereperformed. The coated tablets with a 10mg polymer/cm2SR/IR coating and an 8.5:1.5 coating had the shortest lag times prior to drug release and the onset of floating, as well as the fastest increase in floating strength and highest maximum value. Linear drug release characteristics demonstrated a significant delay in drug release with a time interval of 24 hours. Jangetalpreparedagastro-retentivedrugdelivery system ofDA-6034,anew synthetic flavonoidderivative,forthetreatmentofgastritisusinganeffervescentfloatingmatrixsystem(EFMS).TheEFMSwascreatedtoenablethetabletstofloatingastricfluidandreleasethemedicationconstantly,overcomingthetherapeuticlimitationsofDA-6034causedbyitspoorsolubilityinacidicconditions.

Conclusion:

It is difficult to create an effective FDDS, and the drug delivery system must remain in the stomach for a sufficient amount of time. Different procedures and approaches have been utilized to foster FDDS has arisen as one of the most encouraging gastro-retentive medication conveyance frameworks. For drugs that are primarily absorbed in the upper part of the GIT—the stomach, duodenum, and jejunum—the FDDS has an additional advantage. As of late many medications have been formed as drifting medication conveyance frameworks with a target of supported discharge and limiting the area of medication delivery to stomach. A straightforward and practical strategy for increasing the dosage form's gastric residence time and ensuring sustained drug release is the buoyant preparation principle. For the development of a floating drug delivery system, the dosage form's density must be lower than that of gastric fluid, which is the most crucial requirement. As a result, it can be concluded that these dosage forms are the most effective for obtaining a prolonged effect from a drug with a short half-life and treating GIT-related diseases.

References:

1. Arora S, Ahuja A. Floating drug delivery system: A Review. J. AAPS Pharm Sci Tech 2005; Vol.6 (03): 372-390.
2. Deshpande AA, Rhodes CT, Shah NH, Malick AW. Controlled-release drug delivery systems for prolonged gastric residence: An overview. Drug Dev and Ind Pharm 1996; 22:631-9.
3. Hwang SJ, Park H, Park K. Gastric retentive drug-delivery systems. Crit Rev Ther Drug Carrier Syst 1998; 15:243-83.
4. Degen LP, Peng F, Collet A, Rossi L, Ketterer S, Serrano Y, et al. Blockade of GRP receptors inhibits gastric emptying and gallbladder contraction but accelerates small intestinal transit. Gastroenterology 2001; 120:361-8.
5. Kydoneius A. Controlled Release Technologies. 2nd Ed. New York: Marcel Dekker; 1991; 24-109.
6. Petrakis IE, Kogerakis N, Vrachassotakis N, Stiakakis I, Zacharioudakis G, Chalkiadakis G. Hyperglycemia attenuate erythromycin-induced acceleration of solidphase gastric emptying in healthy subjects. Abdom Imaging 2002; 27:309- 14.
7. Silang R, Regalado M, Cheng TH, Wesson DE. Prokinetic agents increase plasma albumin in hypoalbuminemic chronic dialysis patients with delayed gastric emptying. J Kidney Dis 2001; 37:287- 93.
8. Gupta P and Gnanarajan P K. Floating Drug Delivery System: A Review. Int. J Pharm ResRev.2015;4(8):37-44.
9. Shyama S K and Sivakumar R. Floating Drug Delivery System: An Updated Review. Int, J Curr Pharm Clinical Res. 2014; 4(3):150-53.
10. Parma P D, Pande S, Shah H S, Sonara S N and Patel G H. Floating Drug Delivery System: A Novel Approach to Prolong Gastric Retention. World J Pharma Pharma Sci. 2014; 3(4):418-44.

11. Veerareddy PR, Bajjuri S, Sanka K, Jukanti R, Bandari S and Ajmeru RK. Formulation and Evaluation of Gastro retentive Dosage Form of Ofloxacin. Stamford J Pharma Sci. 2011; 4(1):09-18.
12. NirmalJ,Saisivam S,PeddannaC,MuralidharanS,GodwinkumarSandNagarajanM.Bi-layertabletsofAtorvastatinCalcium andNicotinicacid;Formulationandevaluation.Chem Pharm Bulletin.2008;56(10):1455-58.
13. HamzaYassinEl-SaidandMonaHA.DesignandInVitroEvaluationofNovelSustained-ReleaseDouble-LayerTabletsofLornoxicam:UtilityofCyclodextrinand Xanthan Gum.
14. Chawla G, Gupta P, Koradia V and Bansal AK. Gastroretention: A Means to Address Regional Variability in intestinal drug Absorption, Pharmaceutical technology. 2003; 27(2):50-68.
15. Chandel A, Chauhan K, Parashar B, Kumar H and Arora S Floating drug delivery systems: A better approach. International Current Pharmaceutical Journal. 2012; 1(5):110-118.
16. Rubinstein A and Friend DR. Specific delivery to the gastrointestinal tract, in: A. J. Domb (Ed.), Polymeric site-specific Pharmacotherapy, Wiley, Chichester. 1994; 282-283.
17. Vyas SP and Roop KK. Controlled Drug Delivery Concepts and Advances, First Edition, New Delhi. 2002; 196- 217.
18. Jain NK. Progress in Controlled and Novel Drug Delivery Systems. First Ed. CBSS. Gopalakrishnan. Journal of Pharmaceutical Science and Technology. Publishers and Distributors, New Delhi, Bangalore. 2004; 3(2):84-85.
19. Goyal M, Prajapati R, Purohit KK and Mehta SC. Floating drug delivery system, Journal of current pharmaceutical research. 2011; 5(1): 7-18.
20. Klausner EA, Sara E, Lavy E, Friedman M and Hoffman A. Novel levodopa gastro-retentive dosage form: in-vivo evaluation in dogs. J. Control. Release. 2003; 88:117-126.
21. Kale RD and Tayade PT. A multiple unit floating drug delivery system of Piroxicam using Eudragit polymer. Indian J PharmScie. 2007; 69(1):120- 123.
22. Sangekar S. Evaluation of effect of food and specific gravity of the tablets on gastric retention time. Int J Pharm. 1987; 35(3):34-53.
23. Moursy NM, Afifi NH, Ghorab DM and El-Saharty Y. Formulation and evaluation of sustained release floating capsules of Nicardipine hydrochloride. Pharmazie. 2003; 58: 38-43.
24. Timmermans J, Moes AJ, "How well do floating dosage forms float?'' Int. J. Pharmaceutics.1990, 62, 207-216.
25. TomarP,ShuklaV,KhariaAAandChatterjeeDP.Floatingdrugdelivery system: an updatedreview.JMedPharm Allied Sci.2013;04:31-42.
26. Yang L and Fassihi R. Zero order release kinetics from self-correcting floatable configuration drug delivery system. J Pharm Sci. 1996; 85:170- 173.
27. Burns SJ, Attwood D and Barnwell SG. Assessment of a dissolution vessel designed for use with floating and erodible dosage forms. Int J Pharm. 1998; 160:213-218.
28. Joseph NJ, Laxmi S and Jaya Krishnan A. A floating type oral dosage form for piroxicam based on hollow microspheres: in vitro and in vivo evaluation in rabbits. J Control Release. 2002; 79:71-79.
29. Sheth PR and Tossounian JL. Inventors. Sustained release pharmaceutical capsules. US patent. 1978; 4:126-672.

30. Soppimath KS, Kulkarni AR, Rudzinski WE and Aminabhavi TM. Microspheres as floating drug delivery system to increase the gastric residence of drugs. Drug Metab Rev. 2001; 33:149-160.
31. Ichikawa M, Watanabe S and Miyake Y. A new multiple unit oral floating dosage system. I: Prepration and in vitro evaluation of floating and sustained-release kinetics. J Pharm Sci. 1991; 80:1062-1066.
32. Kamala Kannan V, Pyratchikody A, Viswanadhan VP, "Enhancement of Drugs bioavailability by Floating Drug Delivery System-A Review.'' Int. J. Drug Delivery.2011, 3(4), 558-570.
33. SharmaN,AgarwalD,GuptaMKandKhinchiMP.AComprehensiveReviewon FloatingDrugDeliverySystem.IntJResPharm BiomedSci.2011;2(2):428-41.
34. GadhveMV,LendeLK,TajaneTSand Gaikwad DD. FormulationandDevelopmentofBilayerFloatingTabletofNifedipineusingsurfacesoliddispersio ntechnique.IntJAdvPharm.2016;5(5):117-26.
35. ReddyRS,Rama Chandra CT,HiregoudarS,NidoniUK,KammarM,andRam J.influenceofprocessingconditionsonfunctionalandreconstitutionpropertiesofmilkpowdermade fromOsmanabadigoatmilkbyspraydrying.SmallRuminantRes.2014;119:130–137.
36. Arunachalam A,Karthikeyan M,Kishore K,Prasad PH,Sethuraman S,Ashutosh Kumar SandManidipaS.
37. S.Strübing,T.Abbouda,C.Renata,etal.Newinsightsonpoly(vinylacetate)-basedcoatedfloatingtablets: characterization ofhydrationandCO2generationbybenchtopMRIanditsrelationtodrugreleaseandfloatingstrength .Eur.J.Pharm. Bio pharm.,2008,69:708-717.
38. Geetha A, Rajendra Kumar J. A Review on floating drug delivery system. Int. J. Pharmaceutical Research & Biomedical Analysis, 2012, 1(1), 1-13.
39. DeshpandeA.A.,ShahN.H.,RhodesC.T.,MalickW.,Developmentofanovelcontrolledreleasesyst em forgastricretention,Pharm.Res.1997;14:815-819.
40. JosephN.H.LaxmiS.,JayakrishnanA.Afloatingtypeoraldosagefrom forpiroxicambasedonhollow.
41. BharkatiyaM,KitawatSandOjhaA.Floatingdrugdeliverysystem:Areview.JDrugDelivTher.2014
42. http://www.pharmabiz.com,BasakS,ChronicleSpecials,FloatableGastroretentives:EmergingPo tentials,Mar-2006.
43. KawashiniaY,NiwaT.TakcuchiH.HinoT,ItohY.Hallowmicrospheresforuseasafloatingcontrolle ddrugdeliverysystem inthestomach.J.Pharm.Sci.1992;81(2):135-140.
44. JosephN.H.LaxmiS.,JayakrishnanA.Afloatingtypeoraldosagefrom for Piroxicam basedonhollow Microspheres:invitroand Invivoevaluationinrabbits.J.Cont.Rel.2002;79:71-79
45. Mukhi,U.,&Mohanty,S.(2013).Formulationandevaluationoffloatingtabletsof Cefuroximeaxetil.InternationalJournalofPharmacyandPharmaceuticalSciences,5(SUPPL..4),1 56-161.
46. Pal,P.,Sharma,V.,& Singh,L.(2012).A REVIEW ON FLOATING TYPEGASTRORETENTIVEDRUGDELIVERYSYSTEM PallaviPal*,VijaySharma,LalitSingh.3(4),37-43